VEGF and Nitric Oxide Synthase in Lung Cancer
Author Information
Author(s): S Ambs, WP Bennett, WG Merriam, MO Ogunfusika, SM Oser, MA Khan, RT Jones, CC Harris
Primary Institution: National Cancer Institute
Hypothesis
Oncogenes and tumor suppressors regulate VEGF expression in lung cancer.
Conclusion
The study found no direct regulation of VEGF by p53 in non-small-cell lung cancer (NSCLC).
Supporting Evidence
- VEGF was expressed in 50% of squamous cell carcinomas and carcinoids.
- p53 mutations occurred in 52% of tumors analyzed.
- Ca2+-dependent NOS activity was significantly reduced in lung carcinomas compared to adjacent non-tumor tissue.
Takeaway
This study looked at how certain genes affect a protein that helps tumors grow new blood vessels in lung cancer, but they didn't find a clear link.
Methodology
The study analyzed VEGF protein expression and mutations in p53 and K-ras in 27 non-small-cell lung cancers.
Limitations
The study did not find correlations between VEGF expression and mutations in p53 or K-ras.
Participant Demographics
The study included 27 patients with various types of non-small-cell lung cancer.
Statistical Information
P-Value
p<0.004
Statistical Significance
p<0.004
Want to read the original?
Access the complete publication on the publisher's website